Aptevo Therapeutics Inc.APVONASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank92
3Y CAGR+10.8%
5Y CAGR+77.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+10.8%/yr
vs +33.8%/yr prior
5Y CAGR
+77.6%/yr
Recent deceleration
Acceleration
-23.0pp
Decelerating
Percentile
P92
Near historical high
vs 5Y Ago
17.7x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 21.51% |
| Q2 2025 | -8.40% |
| Q1 2025 | -6.37% |
| Q4 2024 | 25.04% |
| Q3 2024 | -14.82% |
| Q2 2024 | -0.08% |
| Q1 2024 | 1.53% |
| Q4 2023 | -7.62% |
| Q3 2023 | -28.84% |
| Q2 2023 | 31.05% |
| Q1 2023 | -10.83% |
| Q4 2022 | 4.40% |
| Q3 2022 | 15.83% |
| Q2 2022 | -20.57% |
| Q1 2022 | 7.11% |
| Q4 2021 | 4.03% |
| Q3 2021 | -7.52% |
| Q2 2021 | -11.94% |
| Q1 2021 | 9.16% |
| Q4 2020 | 9.30% |
| Q3 2020 | 1.22% |
| Q2 2020 | 10.83% |
| Q1 2020 | -28.64% |
| Q4 2019 | -38.48% |
| Q3 2019 | 18.00% |
| Q2 2019 | 6.15% |
| Q1 2019 | -18.14% |
| Q4 2018 | 3.79% |
| Q3 2018 | -11.73% |
| Q2 2018 | 18.47% |
| Q1 2018 | -10.74% |
| Q4 2017 | 28.03% |
| Q3 2017 | 5.70% |
| Q2 2017 | 14.80% |
| Q1 2017 | -11.31% |
| Q4 2016 | -6.28% |
| Q3 2016 | -6.84% |
| Q2 2016 | -5.74% |
| Q1 2016 | 9.37% |
| Q4 2015 | -3.95% |